[ad_1]
Evaluation of efficacy and safety for patients with moderate disease
In News Reporter Nam Gung-gyeong ㅣ DW2008S, which Donghwa Pharm is developing as a treatment for COVID-19, has been approved for a Phase 2 clinical trial by the Ministry of Food Safety and Drugs.
According to Donghwa Pharm on the 24th, with this approval, a clinical trial is planned to evaluate the efficacy and safety of DW2008S, a natural drug for patients with moderate crown 19.
In addition to DW2008S, Dongwha Pharm is conducting GLP toxicity tests and new drug development tests for two non-clinical studies using a single active ingredient of DW2008S and new drug discovery studies using new derivatives with Ministry support. of Science and the government ICT project.
Meanwhile, DW2008S has demonstrated its safety and tolerability in clinical trials in healthy people at the time of its development as an asthma treatment and is currently planning a Phase 2 clinical trial as an asthma treatment.
Source link
